Skip to main content

. 1957 Jun;36(6 Pt 1):803–809. doi: 10.1172/JCI103485

THE CONCENTRATION AND BINDING OF THYROXINE AND TRIIODOTHYRONINE BY RAT DIAPHRAGM ^¹

John R Hogness ^1,², Norman D Lee ^1,², Margaret K Berg ^1,², Robert H Williams ^1,²

PMCID: PMC441755 PMID: 13439019

803

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

ALBRIGHT E. C., LARSON F. C., TUST R. H. In vitro conversion of thyroxin to triiodothyronine by kidney slices. Proc Soc Exp Biol Med. 1954 May;86(1):137–140. doi: 10.3181/00379727-86-21031. [DOI] [PubMed] [Google Scholar]
CRISPELL K. R., COLEMAN J. A study of the relative binding capacity of plasma proteins, intact human red cells, and human red cell stroma for radioactive I-131 labeled L-thyroxine. J Clin Invest. 1956 May;35(5):475–480. doi: 10.1172/JCI103299. [DOI] [PMC free article] [PubMed] [Google Scholar]
CRISPELL K. R., KAHANA S., HYER H. The effect of plasma on the in vitro uptake or binding by human red cells of radioactive I-131 labeled L-thyroxine and L-triiodothyronine. J Clin Invest. 1956 Jan;35(1):121–124. doi: 10.1172/JCI103246. [DOI] [PMC free article] [PubMed] [Google Scholar]
GROSS J., PITT-RIVERS R. Physiological activity of 3:5:3'-L-triiodothyronine. Lancet. 1952 Mar 22;1(6708):593–594. doi: 10.1016/s0140-6736(52)90104-9. [DOI] [PubMed] [Google Scholar]
GROSS J., PITT-RIVERS R., TROTTER W. R. Effect of 3:5:3'-L-triiodothyronine in myxoedema. Lancet. 1952 May 24;1(6717):1044–1045. doi: 10.1016/s0140-6736(52)90695-8. [DOI] [PubMed] [Google Scholar]
HOGNESS J. R., BERG M., VANARSDEL P. P., Jr, WILLIAMS R. H. Tissue conversion of thyroxine to triiodothyronine. Proc Soc Exp Biol Med. 1955 Oct;90(1):93–97. doi: 10.3181/00379727-90-21949. [DOI] [PubMed] [Google Scholar]
LEE N. D., WILLIAMS R. H. The intracellular localization of labeled thyroxine and labeled insulin in mammalian liver. Endocrinology. 1954 Jan;54(1):5–19. doi: 10.1210/endo-54-1-5. [DOI] [PubMed] [Google Scholar]
MACLAGAN N. F., SPROTT W. E. The in-vitro deiodination of thyroxine and triiodothyronine. Lancet. 1954 Aug 21;267(6834):368–369. [PubMed] [Google Scholar]
MACLAGAN N. F., SPROTT W. E., WILKINSON J. H. Effect of 3:5:3-L-triiodothyronine and certain anti-thyroxine substances on the oxygen consumption of mice. Lancet. 1952 Nov 8;2(6741):915–916. doi: 10.1016/s0140-6736(52)91279-8. [DOI] [PubMed] [Google Scholar]
STADIE W. C. Current views on the mechanisms of insulin action. Am J Med. 1955 Aug;19(2):257–273. doi: 10.1016/0002-9343(55)90378-8. [DOI] [PubMed] [Google Scholar]
STADIE W. C., HAUGAARD N., VAUGHAN M. Studies of insulin binding with isotopically labeled insulin. J Biol Chem. 1952 Dec;199(2):729–739. [PubMed] [Google Scholar]
TOMICH E. G., WOOLLETT E. A. The biological activity of triiodothyronine. Lancet. 1953 Apr 11;1(6763):726–726. doi: 10.1016/s0140-6736(53)91850-9. [DOI] [PubMed] [Google Scholar]
VANARSDEL P., Jr, HOGNESS J. R., WILLIAMS R. H., ELGEE N. Comparative distribution and fate of I131-labeled thyroxine and triiodothyronine. Endocrinology. 1954 Sep;55(3):332–343. doi: 10.1210/endo-55-3-332. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES